BL-1020
≈ 1 min read
Names in other languages
No names in other languages are held for this entry yet.
Article bodies are English and are not machine-translated. A name in another language is not a translation of the article.
BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D 2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.
In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company.
BL-1020 (perphenazine 4-aminobutanoate) is an investigational orally-active antipsychotic for the possible treatment of schizophrenia. The chemical is an ester of GABA and perphenazine; pharmacologically it acts as a D 2 antagonist and GABA agonist. It has shown pro-cognitive effects in the trials.
In March 2013, it went into the II/III trial phase. It has been introduced by BioLineRx, a biopharmaceutical development company.
See also
List of investigational antipsychotics List of investigational bipolar disorder drugs
Text derived from https://en.wikipedia.org/w/index.php?oldid=1371967834 under CC BY-SA 4.0; modifications have been made.